| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| ibandronate sodium | Tablet, film coated | 56.25 mg | Anticipated | Available | Manufacturing | 13/02/2026 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Current | Limited Availability | Manufacturing | 13/02/2026 |
| calcitonin salmon | Injection, solution | 100 IU/mL | Anticipated | Available | Unexpected increase in consumer demand | 13/02/2026 |
| pentetic acid | Injection, powder for | 5 mg | Current | Unavailable | Manufacturing | 13/02/2026 |
| medronic acid | Injection, powder for | 10 mg | Current | Unavailable | Manufacturing | 13/02/2026 |
| sodium valproate | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 13/02/2026 |
| olanzapine | Tablet, orally disintegrating | 10 mg | Current | Limited Availability | Manufacturing | 13/02/2026 |
| Rabies virus | Injection, powder for | 2.5 IU | Anticipated | Available | Manufacturing | 13/02/2026 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 13/02/2026 |
| deferasirox | Tablet, film coated | 180 mg | Current | Limited Availability | Manufacturing | 13/02/2026 |
| progesterone | Pessary | 400 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 13/02/2026 |
| methylphenidate hydrochloride | Capsule, hard | 60 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 13/02/2026 |
| azacitidine | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 13/02/2026 |
| olipudase alfa | Injection, powder for | 4 mg | Anticipated | Available | Manufacturing | 13/02/2026 |
| phenytoin sodium | Injection, solution | 250 mg | Resolved | Available | Manufacturing | 13/02/2026 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Limited Availability | Manufacturing | 13/02/2026 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Current | Limited Availability | Manufacturing | 13/02/2026 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Limited Availability | Manufacturing | 13/02/2026 |
| sumatriptan succinate | Tablet, film coated | 69.99 mg | Current | Unavailable | Manufacturing | 12/02/2026 |
| propofol | Injection, emulsion | 10 g/L | Anticipated | Available | Commercial Changes / Commercial viability | 12/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 400 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 12/02/2026 |
| barium sulfate | Suspension, powder for | 98.453 % w/w | Current | Emergency Supply Only | Commercial Changes / Commercial viability | 12/02/2026 |
| ibuprofen | Injection, solution | 5 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 12/02/2026 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 12.5 mg~40 mg | Current | Unavailable | Manufacturing | 12/02/2026 |
| dabigatran etexilate mesilate | Capsule, hard | 172.95 mg | Current | Unavailable | Manufacturing | 12/02/2026 |
| sildenafil citrate | Tablet, film coated | 70.24 mg | Current | Unavailable | Commercial Changes / Commercial viability | 12/02/2026 |
| sildenafil citrate | Tablet, film coated | 140.48 mg | Current | Limited Availability | Manufacturing | 12/02/2026 |
| ifosfamide | Injection, powder for | 2 g | Anticipated | Available | Manufacturing | 12/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Resolved | Available | Manufacturing | 12/02/2026 |
| reboxetine mesilate | Tablet, uncoated | 5.224 mg | Resolved | Available | Commercial Changes / Commercial viability | 12/02/2026 |
| cyclophosphamide monohydrate | Injection, powder for | 2.138 g | Anticipated | Available | Manufacturing | 12/02/2026 |
| gabapentin | Capsule, hard | 400 mg | Current | Unavailable | Manufacturing | 11/02/2026 |
| clozapine | Oral Liquid, suspension | 50 mg/mL | Current | Unavailable | Manufacturing | 11/02/2026 |
| omeprazole | Capsule, enteric | 20 mg | Resolved | Available | Manufacturing | 11/02/2026 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 160 mg~12.5 mg | Current | Limited Availability | Manufacturing | 11/02/2026 |
| levetiracetam | Solution | 100 mg/mL | Current | Limited Availability | Manufacturing | 11/02/2026 |
| moxonidine | Tablet, film coated | 400 microgram | Current | Unavailable | Manufacturing | 11/02/2026 |
| ondansetron | Tablet, orally disintegrating | 4 mg | Current | Limited Availability | Manufacturing | 11/02/2026 |
| ezetimibe~simvastatin | Tablet | 10 mg~20 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 11/02/2026 |
| sildenafil citrate | Tablet, film coated | 140.48 mg | Current | Limited Availability | Manufacturing | 11/02/2026 |
| metoprolol succinate | Tablet, modified release | 23.75 mg | Resolved | Available | Unexpected increase in consumer demand | 11/02/2026 |
| dorzolamide hydrochloride | Eye Drops, solution | 22.26 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 11/02/2026 |
| desferrioxamine mesilate | Injection, powder for | 2 g | Resolved | Available | Manufacturing | 11/02/2026 |
| lamotrigine | Tablet, dispersible | 100 mg | Resolved | Available | Manufacturing | 11/02/2026 |
| betiatide | Injection, powder for | 1 mg | Current | Unavailable | Manufacturing | 10/02/2026 |
| cyproterone acetate | Tablet, uncoated | 50 mg | Current | Limited Availability | Manufacturing | 10/02/2026 |
| acetylcysteine | Injection, concentrated | 2 g | Resolved | Available | Manufacturing | 10/02/2026 |
| midazolam | Injection, solution | 50 mg | Current | Unavailable | Manufacturing | 10/02/2026 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 10/02/2026 |
| prednisolone acetate~phenylephrine hydrochloride | Eye Drops, suspension | 10 mg/mL~1.2 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 10/02/2026 |
| levonorgestrel~ethinylestradiol | Tablet, uncoated | 150 microgram~30 microgram | Current | Unavailable | Manufacturing | 10/02/2026 |
| elotuzumab | Injection, powder for | 340 mg | Current | Limited Availability | Manufacturing | 10/02/2026 |
| moxonidine | Tablet, film coated | 200 microgram | Current | Limited Availability | Manufacturing | 10/02/2026 |
| doxepin hydrochloride | Capsule, hard | 11.3 mg | Current | Unavailable | Manufacturing | 10/02/2026 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 10/02/2026 |
| fenofibrate | Tablet | 48 mg | Discontinued | Unavailable | Manufacturing | 10/02/2026 |
| daptomycin | Injection, powder for | 500 mg | Resolved | Available | Manufacturing | 10/02/2026 |
| daptomycin | Inhalation, powder for | 350 mg | Resolved | Available | Manufacturing | 10/02/2026 |
| stannous chloride dihydrate | Injection, powder for | 19.2 microgram/mL | Current | Unavailable | Manufacturing | 10/02/2026 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 26.9 mg~100 mg | Current | Limited Availability | Manufacturing | 10/02/2026 |
| cabergoline | Tablet, uncoated | 1 mg | Anticipated | Available | Manufacturing | 10/02/2026 |
| flunitrazepam | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 10/02/2026 |
| simvastatin | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 10/02/2026 |
| prazosin hydrochloride | Tablet, uncoated | 5.476 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 9/02/2026 |
| finasteride | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 9/02/2026 |
| amlodipine besilate~atorvastatin calcium trihydrate | Tablet, film coated | 13.88 mg~86.751 mg | Current | Limited Availability | Manufacturing | 9/02/2026 |
| ezetimibe~simvastatin | Tablet | 10 mg~80 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 9/02/2026 |
| topotecan hydrochloride | Injection, concentrated | 4.346 mg | Current | Limited Availability | Unexpected increase in consumer demand | 9/02/2026 |
| sunitinib | Capsule | 25 mg | Anticipated | Available | Manufacturing | 9/02/2026 |
| agomelatinecitric acid | Tablet, film coated | 44.739 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 9/02/2026 |
| valsartan~sacubitril | Tablet, film coated | 51.4 mg~48.6 mg | Current | Unavailable | Manufacturing | 9/02/2026 |
| betahistine dihydrochloride | Tablet | 16 mg | Current | Limited Availability | Manufacturing | 9/02/2026 |
| varenicline tartrate | Tablet, film coated | 1.71 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 9/02/2026 |
| labetalol hydrochloride | Tablet, film coated | 200 mg | Current | Limited Availability | Manufacturing | 9/02/2026 |
| doxepin hydrochloride | Capsule, hard | 28.25 mg | Current | Unavailable | Manufacturing | 9/02/2026 |
| atovaquone~proguanil hydrochloride | Tablet, film coated | 62.5 mg~25 mg | Resolved | Available | Unexpected increase in consumer demand | 9/02/2026 |
2026年2月16日